Evidence map›Paper›PMID 26823744›Full record

ArticleInternational journal of clinical and experimental pathology2015

CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Lili Wang, Qin Liu, Dongliang Lin, Maode Lai

Open access · greenAbstract readComparative Study
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Intratumoral heterogeneity of CD44v6 in rectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lili WangDepartment of Pathology, School of Medicine, Zhejiang UniversityHangzhou 310058, Zhejiang, China; Key Laboratory of Disease Proteomics of Zhejiang Province Hangzhou 310058Zhejiang, China.
Qin LiuDepartment of Pathology, School of Medicine, Zhejiang UniversityHangzhou 310058, Zhejiang, China; Key Laboratory of Disease Proteomics of Zhejiang Province Hangzhou 310058Zhejiang, China.
Dongliang LinDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao University Qingdao, China.
Maode LaiDepartment of Pathology, School of Medicine, Zhejiang UniversityHangzhou 310058, Zhejiang, China; Key Laboratory of Disease Proteomics of Zhejiang Province Hangzhou 310058Zhejiang, China.
Zhejiang University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aim to investigate the variation of CD44v6 expression in the normal-adenoma-primary carcinoma-liver metastasis sequence and its prognostic impact on colorectal carcinomas. The difference in CD44v6 expression between the tumor center and invasive front was also assessed. Immunohistochemistry was performed for CD44v6 on two cohorts. The first was tissue microarrays including 402 primary CRCs sampled from the tumor center and the invasive margin. The second was whole-tissue sections, consisting of 217 adenomas, 72 primary carcinomas, and the corresponding metastatic carcinomas. In the first cohort, we found that CD44v6 down-regulation was inclined to lymph node metastasis and perineural invasion, and had an unfavorable prognosis compared with CD44v6 up-regulation. In the second cohort, CD44v6 expression was predominant in adenoma over primary carcinoma and liver metastasis in multiple steps (normal < adenoma > primary carcinoma and liver metastasis). In addition, our analysis showed that CD44v6 expression was decreased at the invasion front of the CRC compared with the center of the tumor. In conclusion, the maximal expression of CD44v6 in adenoma plays a crucial role in colorectal carcinogenesis, while loss of CD44v6 expression on the cell surface of the tumor edge enhances the progression of metastasis. CD44v6 down-regulation is an independent prognostic factor for strikingly worse disease-specific survival.

Indexed as

AdenomaAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaColorectal NeoplasmsDisease-Free SurvivalDisease ProgressionDown-RegulationFemaleHumansHyaluronan ReceptorsImmunohistochemistryKaplan-Meier EstimateLiver NeoplasmsBiomarkers, TumorCD44v6 antigenHyaluronan ReceptorsadenomaCD44v6colorectal carcinomaimmunohistochemistrymetastasis

Identifiers

PMID26823744
PMCPMC4713530
OpenAlexW2397874552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.